{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:22Z","timestamp":1791994582376,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,3,18]],"date-time":"2027-03-18T00:00:00Z","timestamp":1805328000000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["R01-AR071653"],"award-info":[{"award-number":["R01-AR071653"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013238","name":"Mahidol University Faculty of Medicine Siriraj Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003157","name":"Myasthenia Gravis Foundation of America Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003157","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jid.2025.09.373","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:45:37Z","timestamp":1762206337000},"page":"914-920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Boom or Bust: Clinical Trials in Pemphigus and Other B-Cell\u2013Mediated Autoimmune Diseases"],"prefix":"10.1016","volume":"146","author":[{"given":"Chuda","family":"Rujitharanawong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9389-7918","authenticated-orcid":false,"given":"Aimee S.","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2025.09.373_bib1","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jid.2025.09.373_bib2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bjd.14405","article-title":"Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus","volume":"175","author":"Boulard","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.09.373_bib3","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (Advance IV): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Broome","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2025.09.373_bib4","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMra2312718","article-title":"Neonatal Fc receptor - biology and therapeutics","volume":"392","author":"Bussel","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2025.09.373_bib5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/bjd.18482","article-title":"Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect","volume":"182","author":"Chen","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.09.373_bib6","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jid.2025.09.373_bib8","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(14)61495-1","article-title":"Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"385","author":"Ghanima","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2025.09.373_bib9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjd.20782","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.09.373_bib10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jid.2025.09.373_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00378","article-title":"Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)","volume":"21","author":"Howard","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jid.2025.09.373_bib13","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"issue":"5S","key":"10.1016\/j.jid.2025.09.373_bib36","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.jid.2023.03.646","article-title":"Design of marigold-bp: a phase 2\/3 study of nipocalimab in adults with moderate to severe bullous pemphigoid","volume":"143","author":"Joly","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.09.373_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jid.2025.09.373_bib15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/bjd.19718","article-title":"Establishing cut-off values for mild, moderate, and severe disease in pemphigus patients using the pemphigus Disease Area Index","volume":"184","author":"Krain","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.09.373_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231205431","article-title":"Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study","volume":"14","author":"Kuter","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jid.2025.09.373_bib17","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1111\/ajt.13902","article-title":"Inflammation causes resistance to anti-CD20-mediated B cell depletion","volume":"16","author":"Laws","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jid.2025.09.373_bib18","article-title":"CLEaring the path for cutaneous lupus erythematosus clinical trials: expert recommendations for the use of CLASI to evaluate treatment response","author":"Lu","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jid.2025.09.373_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92253","article-title":"Stat3 regulates desmoglein 3 transcription in epithelial keratinocytes","volume":"2","author":"Mao","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.jid.2025.09.373_bib20","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"MG-ADL: still a relevant outcome measure","volume":"44","author":"Muppidi","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jid.2025.09.373_bib21","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jid.2024.02.023","article-title":"Efficacy and safety of rilzabrutinib in pemphigus: pegasus phase 3 randomized study","volume":"144","author":"Murrell","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.09.373_bib22","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2025.09.373_bib24","doi-asserted-by":"crossref","first-page":"e852","DOI":"10.1111\/jdv.18318","article-title":"Phase 2 BELIEVE study part B: efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris [e-pub ahead of print]","volume":"36","author":"Murrell","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2025.09.373_bib23","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjd.20431","article-title":"Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study","volume":"185","author":"Murrell","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.09.373_bib25","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1074\/jbc.M309000200","article-title":"Pemphigus vulgaris IgG and methylprednisolone exhibit reciprocal effects on keratinocytes","volume":"279","author":"Nguyen","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jid.2025.09.373_bib26","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/brain\/awae400","article-title":"Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial","volume":"148","author":"Nobile-Orazio","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.jid.2025.09.373_bib27","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study","volume":"98","author":"Nowak","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.jid.2025.09.373_bib28","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jid.2025.09.373_bib29","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/1346-8138.12649","article-title":"Grading criteria for disease severity by pemphigus disease area index","volume":"41","author":"Shimizu","year":"2014","journal-title":"J Dermatol"},{"key":"10.1016\/j.jid.2025.09.373_bib32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2025.09.373_bib33","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in Patients with pemphigus vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2025.09.373_bib34","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.jid.2023.03.1673","article-title":"The importance of patient-focused drug development in pemphigus and pemphigoid","volume":"143","author":"Yale","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.09.373_bib35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jdermsci.2021.07.002","article-title":"A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral bruton's tyrosine kinase inhibitor, in pemphigus","volume":"103","author":"Yamagami","year":"2021","journal-title":"J Dermatol Sci"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25034049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25034049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:03:22Z","timestamp":1780722202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X25034049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0022202X25034049"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2025.09.373","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Boom or Bust: Clinical Trials in Pemphigus and Other B-Cell\u2013Mediated Autoimmune Diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2025.09.373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}